These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31021170)

  • 21. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
    Aardoom MA; Veereman G; de Ridder L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
    Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease.
    Franca R; Curci D; Lucafò M; Decorti G; Stocco G
    Expert Opin Drug Metab Toxicol; 2019 Jul; 15(7):527-539. PubMed ID: 31177858
    [No Abstract]   [Full Text] [Related]  

  • 24. Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?
    Nuij V; Fuhler GM; Edel AJ; Ouwendijk RJ; Rijk MC; Beukers R; Quispel R; van Tilburg AJ; Tang TJ; Smalbraak H; Bruin KF; Lindenburg F; Peyrin-Biroulet L; van der Woude CJ;
    J Crohns Colitis; 2015 Nov; 9(11):997-1003. PubMed ID: 26223842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
    Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rare occurrence of inflammatory bowel disease in a cohort of Han Chinese ankylosing spondylitis patients- a single institute study.
    Wang CR; Weng CT; Lee CT; Huang KY; Hsu SM; Liu MF
    Sci Rep; 2017 Oct; 7(1):13165. PubMed ID: 29030592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study.
    de Klaver PAG; Keizer RJ; Ter Heine R; Smits L; Boekema PJ; Kuntzel I; Schaap T; de Vries A; Bloem K; Rispens T; Hoentjen F; Derijks LJJ
    Eur J Drug Metab Pharmacokinet; 2023 Jul; 48(4):377-385. PubMed ID: 37322238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
    Assa A; Matar M; Turner D; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Shamir R
    Gastroenterology; 2019 Oct; 157(4):985-996.e2. PubMed ID: 31194979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical utility of serum concentrations of adalimumab as predictor of treatment adherence.
    Sáez Belló M; Llopis Salvia P; Alegre Sancho JJ; Paredes Arquiola JM; Asencio Muñoz MDC; Climente Martí M
    Reumatol Clin (Engl Ed); 2020; 16(1):32-37. PubMed ID: 29500118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice.
    Aguas Peris M; Bosó V; Navarro B; Marqués-Miñana MR; Bastida G; Beltrán B; Iborra M; Sáez-González E; Monte-Boquet E; Poveda-Andrés JL; Nos P
    Inflamm Bowel Dis; 2017 Aug; 23(8):1454-1460. PubMed ID: 28708805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low muscle mass at initiation of anti-TNF therapy for inflammatory bowel disease is associated with early treatment failure: a retrospective analysis.
    Holt DQ; Varma P; Strauss BJG; Rajadurai AS; Moore GT
    Eur J Clin Nutr; 2017 Jun; 71(6):773-777. PubMed ID: 28225051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
    Yanai H; Lichtenstein L; Assa A; Mazor Y; Weiss B; Levine A; Ron Y; Kopylov U; Bujanover Y; Rosenbach Y; Ungar B; Eliakim R; Chowers Y; Shamir R; Fraser G; Dotan I; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):522-530.e2. PubMed ID: 25066837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.
    Protic M; Schoepfer A; Yawalkar N; Vavricka S; Seibold F
    Scand J Gastroenterol; 2016 Dec; 51(12):1482-1488. PubMed ID: 27534974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.
    Steenholdt C; Bendtzen K; Brynskov J; Ainsworth MA
    Inflamm Bowel Dis; 2016 Aug; 22(8):1999-2015. PubMed ID: 27135483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.
    Ben-Horin S; Mazor Y; Yanai H; Ron Y; Kopylov U; Yavzori M; Picard O; Fudim E; Maor Y; Lahat A; Coscas D; Eliakim R; Dotan I; Chowers Y
    Aliment Pharmacol Ther; 2012 Mar; 35(6):714-22. PubMed ID: 22288419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors.
    Moss AC; Brinks V; Carpenter JF
    Aliment Pharmacol Ther; 2013 Nov; 38(10):1188-97. PubMed ID: 24118102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Outcomes of Proactive Therapeutic Drug Monitoring of Adalimumab and Standard of Care in Patients With Inflammatory Bowel Disease.
    Dai C; Jiang M; Yu JH
    J Crohns Colitis; 2019 Aug; 13(8):1092-1093. PubMed ID: 30753387
    [No Abstract]   [Full Text] [Related]  

  • 38. Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel Disease.
    Buffone E; Gupta S; Al Ibrahim B; Marshall JK; Halder S; Tse F; Albashir S; Morgan D; Lumb B; Armstrong D; Narula N
    J Clin Gastroenterol; 2022 Oct; 56(9):794-797. PubMed ID: 34753872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up.
    Chen DY; Chen YM; Hsieh TY; Hung WT; Hsieh CW; Chen HH; Tang KT; Lan JL
    Rheumatology (Oxford); 2016 Jan; 55(1):143-8. PubMed ID: 26324949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic drug monitoring in inflammatory bowel disease.
    Jossen J; Dubinsky M
    Curr Opin Pediatr; 2016 Oct; 28(5):620-5. PubMed ID: 27583410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.